Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Homology Medicines

Status and phase: Withdrawn; Phase 1

Conditions: Mucopolysaccharidosis II

Treatments: Biological: Genetic HMI-203

Study type: Interventional

Funder types: Industry

Identifiers

NCT05238324

HMI-203-101

Details and patient eligibility

About

Phase 1, open-label, sequential ascending dose-escalation study. Designed to evaluate the safety and efficacy of a single IV infusion of investigational gene therapy HMI-203. Males, ages 18 to 45 years inclusive, with MPS II (Hunter syndrome) currently receiving idursulfase ERT (or the equivalent) are eligible to participate. Participants will be followed for safety and efficacy for 5 years.

Full description

This Phase 1 study will evaluate the safety and efficacy of HMI-203 gene therapy in adult male participants with MPS II currently being treated with standard-of-care idursulfase ERT or equivalent. Participants will receive a single dose of HMI-203 administered intravenously. There are 3 planned dose cohorts which will consist of 3 participants each.

Entry into the first dose cohort will be separated by a 60-day dosing interval between each participant to allow the Homology Medicines medical monitor to review safety and efficacy data prior to the second and third participants being enrolled. Enrollment of subsequent participants, in cohorts 2 and 3, will be separated by a 21-day dosing interval between each participant for review of safety and efficacy data.

Escalation to the next dose cohort will occur after 21 days of safety, efficacy, and biomarker data have been reviewed by the Homology Medicines independent DMC.

This entire study is comprised of 5 years, with the most frequent follow up visits occurring in the first year.

Sex: Male

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Adult males 18-45 years of age at the time of informed consent
• Has capacity and is able to understand the purpose and risks of the study and is willing, able and committed to comply with all study procedures for the duration of the trial (a total of 5 years after gene therapy administration)
• Diagnosis of MPS II based on historically decreased I2S enzyme activity and elevated urine GAGs and/or presence of hemizygous IDS pathogenic variant
• Kaufman Brief Intelligence Test-Second Edition (KBIT2) score ≥ 80
• Compliance with regular treatments of ERT for MPS II for at least 12 months prior to enrollment
• Clinically stable relative to urinary GAG levels, ambulation, and cardiopulmonary status for 12 months preceding enrollment

Key Exclusion Criteria:

• Multiple sulfatase disorder as determined by abnormal activity of another lysosomal sulfatase
• Unresponsive and/or intolerant to idursulfase treatment
• History of BMT, stem cell transplant, or gene therapy
• Presence of anti-capsid neutralizing antibodies
• ALT or AST > ULN; Total or Direct bilirubin > ULN
• International normalized ratio (INR) >1.2 ULN
• Hematology values below the normal range
• Hemoglobin A1c ≥ 6.5% or fasting glucose ≥126 mg/dL
• Contraindication to corticosteroid or tacrolimus use
• Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study or, in the opinion of the investigator, makes the potential participant unsuitable for the study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

0 participants in 3 patient groups

HMI-203 Low Dose Level Cohort 1

Experimental group

Treatment:

Biological: Genetic HMI-203

HMI-203 Intermediate Dose Level Cohort 2

Experimental group

Treatment:

Biological: Genetic HMI-203

HMI-203 High Dose Level Cohort 3

Experimental group

Treatment:

Biological: Genetic HMI-203